바이오스펙테이터

바이오스펙테이터 Sungmin Kim 기자

Korea Investment Partners Co., Ltd. and SBI Investment participated in the Subsequent Investment … KTB Network and K2 Investment joined as New Investors.

Qu-BEST BIO announced that the company successfully invited an investment of 9-Billion KRW for Series B on October 15, 2020. This succeeds an initial investment of 4-Billion KRW for Series A two years ago.

By following the investment for “Series A”, the Korea Investment Partners Co., Ltd. and SBI Investment participated in the subsequent investment. KTB Network and K2 Investment joined as new institutions of investment.

Qu-BEST BIO has been reinforcing its specialty in the field of non-clinical trial for research and development of medicine for more than 10 years. The company established the “Non-Clinical Evaluation Center” through an investment of 10 Billion KRW invited for Series A in 2018 at Dong-baek District, Yongin City, Gyeonggi-do Province, Korea, wherein services including drug behaviors, drug metabolism, bio-analysis, molecular cell service, including drug efficacy and pharmacology, assessment of toxicity, and so on are provided. Besides, together with overseas companies of CRO partnership, the center also provides non-clinical data.

President Kin Su-hyeon of Qu-BEST BIO stated, “… the verified service capability of the company, which is specialized in the field of non-clinical research and development of new drugs, will be reinforced through this investment …”, “… the capability of the company as “Enabling Partners” for start-ups and biotech companies as our customers will be intensified further through cooperation with investment companies and development companies to secure significant competitiveness and role in the ecosystem of biopharmaceutical industry.”

CROs became significant partners, participating in cooperation of the field of nonclinical trial for new drug development along with emergence of the recent pandemic of COVID 19 which is turning into an opportunity for biopharmaceutical industries. Qu-BEST BIO focuses on the provision of services embracing initial nonclinical development strategy for new drugs, toxicity test for GLP development, and services for initial development of new drugs before entering into clinical trials. New drug development of over 100 bio- and pharmaceutical companies are currently supported by services provided by Qu-BEST BIO.

Hwang Man-soon, the Chief Investment Officer (CIO) of Korea Investment Partners Co., Ltd., stated, “… along with the rapid increase in expenses for research and development for new drugs of pharmaceutical companies, the open innovation strategy to improve productivity has been introduced to these companies…”, “…Qu-BEST BIO is expected to become a one-stop solution provider in the mutual relationship to survive together as a partner for the development of new drugs, rather than a company providing traditional and functional nonclinical services…”.